ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0612

Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response

Siddharth Jain1, Bidya Laishangtham1, Aastha Khullar1, Biman Saikia1 and Varun Dhir2, 1Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER, CHD, INDIA, Chandigarh, India

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Disease-Modifying Antirheumatic Drugs (Dmards), Natural Killer Cells, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: It is still unclear whether Natural Killer (NK) and Natural Killer T (NKT) cells play a pathogenic or protective role in Rheumatoid Arthritis (RA). There is no data on the effect of methotrexate (MTX), which is the first line of therapy for RA, on NK and NKT cells and their immunophenotypic subsets.

Methods: Two groups of RA patients (2010 ACR/EULAR criteria) aged 18-60 years – Treatment naïve RA with active disease (SJC≥2, TJC≥4) and MTX-treated RA (≥15 mg/week MTX for ≥6 months)- were included, along with age-and-sex-matched healthy controls (HC). Peripheral blood (PB) (and synovial fluid (SF), where available) mononuclear cells (MCs) were isolated through Ficoll Histopaque density gradient centrifugation, and the proportion of NK cells (CD56+CD3–), their subsets (CD56dimCD3–, CD56briCD3–, CD56+CD16+CD3–) and NKT cells (CD56+CD3+) were quantified through flow cytometry and compared between groups.

Results: A total of 138 subjects [68 naïve RA, 47 MTX-treated RA, and 23 HC; mean age 42 (10) years, 118 (85%) females] were included. Mean DAS28-ESR in naïve RA and MTX-treated RA was 6.2 (1.0) and 4.8 (1.0), respectively. The proportion of PB NK cells was found to be lower (p=0.009) in MTX-treated RA (7.8%) compared to naïve RA (11.5%) and HC (12%) (Figure 1A), while the proportion of NKT cells was similar in the three groups (3.75%, 4.6% and 5.1%) (Figure 1B). On NK cell subset analysis, CD56dimCD3– and CD16+CD56+CD3– cells were lower in MTX-treated RA (7.1%, p=0.01 and 6.4%, p=0.02 respectively) compared to naïve RA (10% and 9.7%) and healthy controls (11.4% and 10.3%), while the CD56briCD3– population was similar across all three groups (Figure 1C-E). SFMCs were available for 9 RA patients. Comparison of PB and SF NK and NKT cells showed that SFNK had a significantly lower proportion of dual positive (CD16+CD56+CD3–) NK cells (33%) compared to PB (91%, p=0.01), suggesting a predominant secretory rather than a cytotoxic phenotype of SFNK cells.

Conclusion: Peripheral blood and synovial fluid have contrasting NK cell immunophenotypes. Treatment with MTX reduces the proportion of peripheral blood NK cells, particularly the CD56dimCD3– and CD16+CD56+CD3– (dual positive) subsets, in patients with active RA.

Supporting image 1

Figure 1: Comparison of the proportion of NK cells (A), NKT cells (B), and immunophenotypic subsets of NK cells [CD56briCD3- (C), CD56dimCD3- (D), CD56+CD16+CD3- (E)] in the three groups.


Disclosures: S. Jain, None; B. Laishangtham, None; A. Khullar, None; B. Saikia, None; V. Dhir, None.

To cite this abstract in AMA style:

Jain S, Laishangtham B, Khullar A, Saikia B, Dhir V. Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/peripheral-blood-and-synovial-fluid-natural-killer-nk-and-natural-killer-t-nkt-cell-immunophenotypes-in-active-rheumatoid-arthritis-and-their-role-as-biomarkers-of-methotrexate-response/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peripheral-blood-and-synovial-fluid-natural-killer-nk-and-natural-killer-t-nkt-cell-immunophenotypes-in-active-rheumatoid-arthritis-and-their-role-as-biomarkers-of-methotrexate-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology